Suppr超能文献

人 ENT1 与腺苷再摄取抑制剂复合物的结构。

Structures of human ENT1 in complex with adenosine reuptake inhibitors.

机构信息

Department of Biochemistry, Duke University Medical Center, Durham, NC, USA.

出版信息

Nat Struct Mol Biol. 2019 Jul;26(7):599-606. doi: 10.1038/s41594-019-0245-7. Epub 2019 Jun 24.

Abstract

The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Because of its central role in adenosine signaling, it is the target of adenosine reuptake inhibitors (AdoRI), several of which are used clinically. Despite its importance in human physiology and pharmacology, the molecular basis of hENT1-mediated adenosine transport and its inhibition by AdoRIs are limited, owing to the absence of structural information on hENT1. Here, we present crystal structures of hENT1 in complex with two chemically distinct AdoRIs: dilazep and S-(4-nitrobenzyl)-6-thioinosine (NBMPR). Combined with mutagenesis study, our structural analyses elucidate two distinct inhibitory mechanisms exhibited on hENT1 and provide insight into adenosine recognition and transport. Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1.

摘要

人源平衡核苷转运蛋白 1(hENT1)是 SLC29 家族的一员,在人类腺苷信号转导、细胞摄取核苷用于 DNA 和 RNA 合成以及核苷衍生的抗癌和抗病毒药物转运中发挥着关键作用。由于其在腺苷信号转导中的核心作用,它是腺苷再摄取抑制剂(AdoRI)的作用靶点,其中几种已在临床上使用。尽管 hENT1 在人类生理学和药理学中具有重要意义,但由于缺乏 hENT1 的结构信息,其介导的腺苷转运及其被 AdoRIs 抑制的分子基础仍很有限。在这里,我们展示了 hENT1 与两种化学上不同的 AdoRI(地拉卓和 S-(4-硝基苄基)-6-硫代次黄嘌呤(NBMPR))复合物的晶体结构。结合突变研究,我们的结构分析阐明了 hENT1 上表现出的两种不同的抑制机制,并为腺苷识别和转运提供了深入的了解。我们的研究为改善 hENT1 对腺苷和核苷类似物药物转运的药理学干预提供了一个平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d52/6705415/1a26f0a68f8b/nihms-1528933-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验